Publication: Lupus Science & Medicine
Abstract
Mycophenolic acid (MPA) is used to treat pediatric lupus nephritis, but its high pharmacokinetic variability contributes to inconsistent efficacy, and data on genetic and clinical drivers of this variability in children are scarce. This prospective study in 51 pediatric lupus nephritis patients measured steady-state MPA concentrations and screened 29 genetic variants across 13 candidate genes, building a population pharmacokinetic model with Phoenix NLME software. Eight genetic variants across three genes significantly affected MPA exposure, but when combined with clinical variables, body weight emerged as the dominant covariate for MPA's peripheral volume of distribution. The findings suggest body weight, more than pharmacogenetic variation, should guide individualized initial dosing and adjustment of mycophenolate mofetil in pediatric lupus nephritis.
Author(s): Ye C, Liu B, Chen L, Zhang L, Zheng Y, Tang K, Jiang X, Chen P.
Published: 2025 年 7 月 1 日
Phoenix NLME：Weighing Genetics Against Body Weight
Phoenix NLME combined genetic and clinical covariates in this pediatric lupus nephritis study, helping show that body weight, more than genotype, should guide dosing. As part of a Phoenix platform built on a validated, secure foundation, Phoenix NLME remains the engine behind population PK/PD modeling, combining the flexibility of code with the ease of a guided interface.
